What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Caris Life Sciences Shares Surge on Q4 Earnings Beat and Cancer Detection Breakthrough

Caris Life Sciences (CAI) reported fourth-quarter financial results that exceeded analyst expectations, marking a strong conclusion to the fiscal year. Alongside the earnings beat, the company unveiled significant interim data from its Achieve 1 study, showcasing a major breakthrough in early cancer detection technology. This dual catalyst of financial outperformance and clinical success triggered a positive reaction among market participants. Consequently, shares of the company rose during Friday's premarket trading session as investor optimism grew. Analysts view these developments as a significant milestone for the biotech firm's long-term growth prospects. The positive clinical results are expected to strengthen the company's position within the competitive healthcare diagnostics sector.

Caris Life Sciences Shares Surge on Q4 Earnings Beat and Cancer Detection Breakthrough

Key Facts

Social Buzz

Instruments